Drug intelligence / Profile preview

APB-B007

Development stage: Preclinical
Lead developer: APITBIO
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

APB-B007 is a preclinical-stage bispecific antibody being developed by APITBIO for the treatment of solid cancers. It is designed to target CD171 (also known as L1 cell adhesion molecule or L1CAM), a cell surface glycoprotein often overexpressed in various aggressive tumors, alongside a second undisclosed target. By engaging two distinct antigens, APB-B007 aims to enhance tumor specificity and therapeutic efficacy compared to conventional monoclonal antibodies. The program is currently in the discovery phase and has been identified by the developer as available for co-research opportunities.

Targets

L1CAM

Beyond the preview

Go deeper on APB-B007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APB-B007.

Explore the full profile